Introduction
Bisphosphonate-related osteonecrosis of the jaws (BONJ) has been recently described as a severe side effect among patients who have a previous history of chronic bisphosphonate treatment. The very first paper describing Bisphosphonate-related osteonecrosis of the jaws (BRONJ) was published in 2003 (1) . In 2014 American Association of Oral and Maxillofacial Surgeons (AAOMS) suggested that the nomenclature of BRONJ should be changed to Medication-related osteonecrosis of the jaws (MRONJ), due to the trend of increasing number of cases induced by other antiresorptive and antiangiogenic medicaments (2) .
Pathogenesis
Bisphosphonates are widely used in the management of osteoporosis, malignant bone metastasis, Paget`s disease and multiple myeloma (3, 4) . Their proposed mechanisms of action include:
• Inhibition of osteoclast activation and differentiation of their precursors.
• Inhibition of the activity of osteoclasts due to osteoblast-mediated signals.
• Suppressive effect on the function of mature osteoclasts.
• Direct and indirect apoptosis of osteoclasts.
• Inhibition of the dissemination of tumor cells and their adhesion to the bone structures (5) . On the other hand, osteoclasts play an essential role into the process of bone remodeling and bone metabolism. Proposed hypothesis suggest that the predilection of this condition for the jaws is owed to the constant micro trauma during mastication and the persistence of resident bacteria in the oral cavity. Further aberration in bone metabolism and inhibition of the angiogenesis during treatment with bisphosphonates or other antiresorptive medicaments, is consequent to increased chance of developing ONJ (6) . Local factors responsible for the predilection are any periodontal or surgical manipulations onto the dentoalveolar crest (tooth extraction, implants and etc.). Anatomical features, such as palatal torus or thin mucosa make the jaws more susceptible to trauma. (2) In 2005 Aaron P. Sarathy and coworkers, published a paper presenting two cases of MRONJ triggered by endodontic treatment (7) .
Incidence
According to a 2008 study from Aliya Khan, 95% of the patients with BRONJ have history of high dose intravenous bisphosphonates treatment for bone metastasis, while patients treated with small doses bisphosphonates per os represented only 5% from the cases (8) . The incidence of medication-related osteonecrosis among patients with oncological condition depends on the dosage and the duration of the treatment (9). Kahn and coworkers concluded in their study that BRONJ occurs in 1-12% of the cases after 36 months of treatment with bisphosphonates. Furthermore, the incidence of BRONJ among patients, who has gone through oral treatment for several years (etc. treatment of osteoporosis) is less than 1 in 100 000 cases per year (8) .
Diagnose and staging
According to the American Association of Oral and Maxillofacial Surgeons patients can be diagnosed with MRONJ, if the following conditions exist:
• History of previous or current treatment with antiresorbtive or antiangiogenic medicaments.
• No history of radiation therapy in the maxillofacial region. Exposed bone or bone that can be probed through extra or intraoral fistula in the maxillofacial region that has persisted more than 8 weeks (2). Stage 2 Exposed/Necrotic bone associated with infection as evidenced by pain and erythema in the region of the exposed bone with or without purulent drainage.
Ruggiero suggested in
Stage 3 Exposed/Necrotic bone in patients with pain, infection and one or more of the following: Pathologic fracture, extraoral fistula or osteolysis extending to the inferior border.
Clinical characteristics
Exposed bone is common clinical feature of MRONJ. In some complicated cases mobility of the teeth, fistulas, pus discharge and bone fractures can be observed. Clinically, MRONJ can be asymptomatic or can have the characteristics of osteomyelitis. Radiographic characteristics are similar to those in patients with osteomyelitis who have not gone through treatment with antiresorptive medicaments (8) .
The study aims to represent a retrospective analysis of group of patients with MRONJ in order to raise awareness among specialists and General Dental Practitioners.
MATERIALS AND METHODS
For the aims of the study a retrospective chart review was performed on 32 patients referred to the Specialized Hospital for Maxillofacial surgery in Sofia, Bulgaria in the period between 2012 and 2016. All the patients were diagnosed with osteonecrosis of the jaw. Patients were elected to meet the diagnostic criteria proposed by The American Association of Oral and Maxillofacial Surgeons.
RESULTS

Demographics
Twenty men (62, 5%) and twelve women (37, 5%) took part in the statistical analysis. The average age of the included patients was approximately 64 years (range from 45 to 86).
Treatment of the primary disease
The most common oncological diagnoses at presenting were prostate and breast cancer. Thirty one of the patients (96,975%) with MRONJ announced that they have been taking antiresorptive medicaments as a treatment therapy for bone metastasis of prostate, testicles, colon and breast cancer. Only one patient (3,125%) was suffering from osteonecrosis of the jaws due to treatment of osteoporosis with oral bisphosphonates. Five patients declared that they have gone through radiation therapy in a different region from the maxillofacial on the occasion of a primary oncological treatment. According to the medical records, six patients were treated with denosumab (Xgeva), twelve -with Zoledronic acid (Zometa) and one -with both medicaments. One patient has threated osteoporosis with Ibandronic acid (Bonviva) (Graphic 1 RT -Radiology treatment; M -male; F -female; Ca -cancer; D -diabetes; AH -arterial hypertension; IHD -ischemic heart disease; COPD -chronic obstructive pulmonary disease
Symptoms and physical findings
Twenty three (71,875%) patients presented with mandibular bone involvement, while in 9 patients (28,125%) the complication involved the maxillary bone. In regards to the physical manifestations, purulent discharge was observed in 7 patients (21,875%), from which one was with extraoral fistula. Facial asymmetry was featured symptom in 9 patients (28,125%) and bone sequestration -in 2 patients (6,25%). Twenty-eight patients (87, 5%) presented with complaining of pain in the evolved region and four patients presented with asymptomatic clinical or radiographic findings. According to the early mentioned clinical staging classification, 28 patients were classified as stage 2 of MRONJ and 4 patients as stage 1 (asymptomatic).
Comorbidity and triggering factors
This group had a large variety of significant comorbidities from which arterial hypertension has found to be the most common (13 patients/ 40,625%). According to the medical records, 25% of the patients were affected by diabetes. Nine patients (28,125%) presented symptoms of pain and exposed bone at the site I S S U E 2 , 2 0 1 7 of previous tooth extraction. Only one patient reported that the symptoms were initiated after placement of implant.
Treatment of MRONJ
All patients were conservatively treated with antibiotics. In addition to the antibiotic regiment in two of the cases (6,25%) was committed sequestrectomy. Five patients (15,625%) were treated with Amoxiclav, with Unasyn -3 (9,375%), with Lyncomicin -23 (71,875%) and with Amikacin -1 (3,125%). Metronidazol was given to 3 patients. Apart from the antibacterial treatment,twenty-four patient were also treated with analgetics (Graphic 2). Improvement in the status was observed in all patients at the moment of their discharge from the hospital ( Table 2) . 
DISCUSSION
In the limits of the study one patient was presented with history of oral treatment with bisphosphonates for management of osteoporosis. The low bio-availability of the oral bisphosphonates in the bone matrix is a result of their low intestinal absorption (from 1% to 10%), which can be additionally reduced if simultaneously taken with Calcium and Ferrum (4 Intravenously taken bisphosphonates have extended storage of the medicament in the bone. Relevant to the oral intake, the intravenous bisphosphonates show significantly higher incidence of developing osteonecrosis of the jaws (4, 11) . According to the medical records, eight patients (25%) were presented with diabetes. The epidemiological data presented in the study of Khamaisi and coworkers, suggested a possible role of diabetes as a risk factor in the development of osteonecrosis of the jaws. In the limits of their study, eighteen patients (58%), have developed MRONJ on the background of comorbid diabetes (12) .
According to the medical literature, the hypothetic role of diabetes in the development of MRONJ is mainly associated with microangiopathogenic ischemia of the bones (13) . The impaired metabolic processes of the bone result in reduced possibility for bone remodeling and apoptosis of the osteoclast and osteoblast (14, 15) . The abnormality of the bone metabolism which is presented in patients with comorbid diabetes additionally aggravates the effect of antiangiogenic and antiresorbtive medicaments, resulting in higher chance of developing of osteonecrosis of the bones. Although, all of the patients were signed out with an improvement in their condition, six of them were referred to the hospital again, due to exacerbation. Two of the exacerbated patients have had complications, classified as stage 3 of osteonecrosis with cutaneous fistula. The conventional treatment with antibiotics and analgesics has been proved to provide satisfying results but not in all cases (16) . Additional examination and tracking of the patients is regarded a necessity, in order to evaluate the results from the treatment accurately. A study from V. Aftimos and coworkers suggested positives effect of antifungal medicaments in the conventional management of MRONJ.
Conclusion
• The incidence of BRONJ among patient on intravenous therapy for bone metastasis is significantly higher than those on oral therapy.
• BRONJ affect the mandibular bone 2,5 times more often than the maxillary bone.
• The most common trigger factor for MRONJ was tooth extraction.
• Diabetes can be related to MRONJ as a predisposing factor.
• In the limits of our study most of the patients with MRONJ seek for medical attention in stage 2 of osteonecrosis.
• The recommended conservative treatment with antibiotics can lead to remission, rather than a full recovery.
